SwingTrade Member Forum

[umiak]

NEOS looks like market temper tantrum is over:

Neos Therapeutics (NEOS) has drifted down in recent months after rejecting a $10.25 a share hostile buyout offer. The shares now trade at just $6.75 apiece. The company did the right thing by rejecting the lowball bid, but investors seeking a quick takeout have largely abandoned the shares as a result. However, Neos now has three approved drugs in the growing ADHD space. This means they can be pushed by the same sales force creating economies of scale.

In addition, the company is seeing very fast uptake of its latest offering and achieved 90% year-over-year sales growth in the first quarter. Neos may need to do one final capital raise if it remains a standalone entity but is cheap with just a $200 million market cap. I believe the company will eventually be acquired, but in the mid-teens range and not at $10.25 a share.

https://realmoney.thestreet.com/articles/06/10/2018/biotech-bargains-two-cheap-small-cap-stocks-exciting-sector?puc=yahoo&cm_ven=YAHOO&yptr=yahoo